{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T03:51:57Z","timestamp":1763697117548,"version":"3.45.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP223fa627002"],"award-info":[{"award-number":["JP223fa627002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP18H05282","22K16344"],"award-info":[{"award-number":["JP18H05282","22K16344"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020408","name":"Kansai Economic Federation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020408","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003382","name":"Core Research for Evolutional Science and Technology","doi-asserted-by":"publisher","award":["22gm1810003h0001","JP18cm059042","20kf0108454h0001","JP18cm016335"],"award-info":[{"award-number":["22gm1810003h0001","JP18cm059042","20kf0108454h0001","JP18cm016335"]}],"id":[{"id":"10.13039\/501100003382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.vaccine.2025.127771","type":"journal-article","created":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T09:53:57Z","timestamp":1760262837000},"page":"127771","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Distinct trajectories of humoral immune responses after SARS-CoV-2 mRNA vaccination in autoimmune inflammatory rheumatic diseases: A group-based trajectory analysis"],"prefix":"10.1016","volume":"66","author":[{"given":"Yuta","family":"Yamaguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saori","family":"Amiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichiro","family":"Inokuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayaka","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"Kosaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Nameki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruaki","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Yoshimine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutaka","family":"Okita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Tsujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Nishide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumiyuki","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Narazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kumanogoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127771_bb0005","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/annrheumdis-2020-218946","article-title":"Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis","volume":"80","author":"Akiyama","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.vaccine.2025.127771_bb0010","doi-asserted-by":"crossref","DOI":"10.1002\/art.42030","article-title":"SARS-CoV-2 infection and COVID-19 outcomes in rheumatic disease: a systematic literature review and Meta-analysis","author":"Conway","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.vaccine.2025.127771_bb0015","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002035","article-title":"Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study","volume":"8","author":"Boekel","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.vaccine.2025.127771_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/ard-2023-223974","article-title":"Outcomes following SARS-CoV-2 infection in individuals with and without inflammatory rheumatic diseases: a Danish nationwide cohort study","volume":"82","author":"Svensson","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.vaccine.2025.127771_bb0025","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002839","article-title":"Risk of COVID-19 among unvaccinated and vaccinated patients with systemic lupus erythematosus: a general population study","volume":"9","author":"Jiang","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.vaccine.2025.127771_bb0030","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1136\/annrheumdis-2021-222045","article-title":"Efficacy of COVID-19 vaccines in patients taking immunosuppressants","volume":"81","author":"Shen","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.vaccine.2025.127771_bb0035","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study","volume":"80","author":"Furer","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.vaccine.2025.127771_bb0040","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keac089","article-title":"Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions","author":"Krasselt","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.vaccine.2025.127771_bb0045","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002050","article-title":"Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses","volume":"8","author":"Saleem","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.vaccine.2025.127771_bb0050","article-title":"Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases","volume":"8","author":"Santos","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.vaccine.2025.127771_bb0055","doi-asserted-by":"crossref","first-page":"102743","DOI":"10.1016\/j.jaut.2021.102743","article-title":"A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases","volume":"125","author":"Tzioufas","year":"2021","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.vaccine.2025.127771_bb0060","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.1016\/S2665-9913(23)00160-1","article-title":"Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY","volume":"5","author":"Pearce","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.vaccine.2025.127771_bb0065","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220461","article-title":"Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease","author":"Simon","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.vaccine.2025.127771_bb0070","doi-asserted-by":"crossref","DOI":"10.1136\/ard-2022-222904","article-title":"Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases","author":"Stalman","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.vaccine.2025.127771_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-002998","article-title":"Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases","volume":"9","author":"Hasseli","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.vaccine.2025.127771_bb0080","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2665-9913(23)00272-2","article-title":"Effectiveness of a fourth dose of COVID-19 mRNA vaccine in patients with systemic autoimmune rheumatic diseases using disease-modifying antirheumatic drugs: an emulated target trial","volume":"6","author":"Hanberg","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.vaccine.2025.127771_bb0085","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002632","article-title":"Reduced humoral response to a third dose (booster) of SARS-CoV-2 mRNA vaccines by concomitant methotrexate therapy in elderly patients with rheumatoid arthritis","volume":"8","author":"Stahl","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.vaccine.2025.127771_bb0090","first-page":"e382","article-title":"Factors associated with poor antibody response to third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases. Lancet","volume":"4","author":"Connolly","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.vaccine.2025.127771_bb0095","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1016\/S2665-9913(22)00034-0","article-title":"Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study","volume":"4","author":"Wieske","year":"2022","journal-title":"Lancet Rheumatology"},{"key":"10.1016\/j.vaccine.2025.127771_bb0100","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1146\/annurev.clinpsy.121208.131413","article-title":"Group-based trajectory modeling in clinical research","volume":"6","author":"Nagin","year":"2010","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"10.1016\/j.vaccine.2025.127771_bb0105","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1146\/annurev-clinpsy-081122-012416","article-title":"Recent advances in group-based trajectory modeling for clinical research","volume":"20","author":"Nagin","year":"2024","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"10.1016\/j.vaccine.2025.127771_bb0110","first-page":"1737","article-title":"Multi-trajectory models of chronic kidney disease progression","volume":"2016","author":"Burckhardt","year":"2016","journal-title":"AMIA Annu Symp Proc AMIA Symp"},{"key":"10.1016\/j.vaccine.2025.127771_bb0115","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002673","article-title":"Latent trajectory modelling of pulmonary artery pressure in systemic sclerosis: a retrospective cohort study","volume":"8","author":"Kida","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.vaccine.2025.127771_bb0120","article-title":"Persistence of SARS-CoV-2 neutralizing antibodies and anti-omicron IgG induced by BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic disease: an explanatory study in Japan","volume":"32","author":"Yamaguchi","year":"2022","journal-title":"Lancet Regional Heal - West Pac"},{"key":"10.1016\/j.vaccine.2025.127771_bb0125","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020683","article-title":"Framework to construct and interpret latent class trajectory modelling","volume":"8","author":"Lennon","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2025.127771_bb0130","doi-asserted-by":"crossref","unstructured":"Xu L, Abudunaibi B, Zeng Z, Zhao Y, Wang Y, Guo X, et al. Relationship of various COVID-19 antibody titer with individual characteristics and prediction of future epidemic trend in Xiamen City, China J Thorac Dis 2024;0:0\u20130. doi:10.21037\/jtd-23-1516.","DOI":"10.21037\/jtd-23-1516"},{"key":"10.1016\/j.vaccine.2025.127771_bb0135","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.168663","article-title":"Diminished responses to mRNA-based SARS-CoV-2 vaccines in individuals with rheumatoid arthritis on immune modifying therapies","volume":"8","author":"Klebanoff","year":"2023","journal-title":"JCI Insight"},{"issue":"81","key":"10.1016\/j.vaccine.2025.127771_bb0140","first-page":"786","article-title":"Updated viewpoints on SARS-CoV-2 vaccination in patients with RMDs: a guidance to answer patients\u2019 questions","volume":"2022","author":"Bijlsma","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.vaccine.2025.127771_bb0145","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/art.42372","article-title":"American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 5","volume":"75","author":"Curtis","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.vaccine.2025.127771_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(22)00186-2","article-title":"Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial","author":"Abhishek","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.vaccine.2025.127771_bb0155","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/annrheumdis-2024-eular.2024","article-title":"POS0071\u00a0immunomodulatory treatment and immune responses to COVID-19 booster shots in patients with autoimmune rheumatic diseases: results from the COVID-19 vaccine response in RHEUMATOLOGY patients (cover) study","volume":"83","author":"Curtis","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.vaccine.2025.127771_bb0160","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/infdis\/jir661","article-title":"Influenza Hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection","volume":"204","author":"Ohmit","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.vaccine.2025.127771_bb0165","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/annrheumdis-2021-221461","article-title":"Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19?","volume":"81","author":"Bower","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.vaccine.2025.127771_bb0170","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.70554","article-title":"Impaired HA-specific T follicular helper cell and antibody responses to influenza vaccination are linked to inflammation in humans","volume":"10","author":"Hill","year":"2021","journal-title":"ELife"},{"key":"10.1016\/j.vaccine.2025.127771_bb0175","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/s41598-023-28295-8","article-title":"Post-vaccination serum cytokines levels correlate with breakthrough influenza infections","volume":"13","author":"Tang","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.vaccine.2025.127771_bb0180","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.3390\/diagnostics11101757","article-title":"Performance of a surrogate SARS-CoV-2-neutralizing antibody assay in natural infection and vaccination samples","volume":"11","author":"Chan","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.vaccine.2025.127771_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2022.105169","article-title":"Evaluation of commercial anti-SARS-CoV-2 neutralizing antibody assays in seropositive subjects","volume":"152","author":"Saker","year":"2022","journal-title":"J. Clin. Virol."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25010680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25010680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T02:57:09Z","timestamp":1763693829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25010680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":37,"alternative-id":["S0264410X25010680"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127771","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct trajectories of humoral immune responses after SARS-CoV-2 mRNA vaccination in autoimmune inflammatory rheumatic diseases: A group-based trajectory analysis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127771","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127771"}}